Indication
Unresectable Perihilar or Ductal CCA
1 clinical trial
3 drugs
Clinical trial
The CLEAN-DUCT / TRITICC-3 Trial - Phase IIa, Prospective, Single Arm, Open Label, Non-randomized, Multi-center Pilot Study of Durvalumab (MEDI4736) + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic CholangiocarcinomaStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Drug
GemcitabineDrug
CisplatinDrug
AN0025